MAZE
Maze Therapeutics, Inc.NASDAQHealthcare$28.71-1.17%ClosedMarket Cap: $1.43B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.48
P/S
0.00
EV/EBITDA
-9.28
DCF Value
$3.86
FCF Yield
-8.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-40.7%
ROA
-33.0%
ROIC
-37.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-38.1M | $-34.6M | $-0.87 | — |
| FY 2025 | $0.00 | -Infinity% | $-142.9M | $-131.1M | $-3.05 | — |
| Q3 2025 | $0.00 | NaN% | $-33.0M | $-30.1M | $-0.66 | — |
| Q2 2025 | $0.00 | -Infinity% | $-36.5M | $-33.7M | $-0.77 | — |
| Q1 2025 | $0.00 | NaN% | $-35.4M | $-32.8M | $-0.75 | — |
| Q4 2024 | $0.00 | NaN% | $-29.7M | $-29.6M | $-0.11 | — |
| FY 2024 | $167.5M | 100.0% | $57.6M | $52.2M | $0.08 | — |
| Q3 2024 | $2.5M | 100.0% | $-24.2M | $-24.8M | $-0.06 | — |
| Q2 2024 | $165.0M | 100.0% | $139.6M | $139.1M | $0.98 | — |
| Q1 2024 | $0.00 | NaN% | $-28.0M | $-32.5M | $-0.74 | — |
| Q4 2023 | $0.00 | NaN% | $-23.1M | $-26.6M | $-0.61 | — |
| FY 2023 | $0.00 | NaN% | $-98.6M | $-100.4M | $-2.29 | — |